FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
|Videos|June 4, 2019
Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Cutaneous Squamous Cell Carcinoma
Advertisement
Case: A 79-Year-Old Male With Metastatic CSCC
April 2016
- A 79-year-old male presented to dermatologist with a large ulcerative lesion on clavicle; he reported lesion first appeared 5 months ago while living in Florida for the winter
- Diagnosed with localized cutaneous squamous cell carcinoma
- Standard surgical excision performed with 4 mm clinical margins; postoperative margins negative
May 2018
- Patient returns to dermatologist for follow-up c/o multiple lesions on shoulder and neck around the site of prior excision
- PE:
- Multiple visible, ulcerated lesions, approximately 2-3cm in diameter; suspected tumor depth >5mm
- Multiple palpable nodes ~2cm
- Imaging confirmed 7 mm invasion into subcutaneous fat; parotid nodal involvement
- Biopsy confirmed cutaneous squamous cell carcinoma, poorly-differentiated
- Diagnosis: Metastatic cutaneous squamous cell carcinoma
- Stage IV: T3N2M0
- Patient started on cemiplimab
Advertisement
Related to this article
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5